


4

5 wherein:


6 m and n are the same or different and each is an integer from 2-8;

7 R is a cationic group or $\text{---C}=\text{O---X}_3$:

8 X₁ is a member selected from the group consisting of



11 and X_2 , and X_3 , are each independently selected from the group consisting of a saccharide,



and wherein at least one of X_2 and X_3 is a saccharide group when R is $\text{---C---}x_3$.

1 **62.** (New) The method of claim 61, wherein said adenoviral vector is
2 selected from the group consisting of a replication competent viral vector, a replication
3 deficient viral vector and a conditionally replicating viral vector.

1 **63.** (New) The method of claim 61, wherein said tumor suppressor
2 gene is selected from the group consisting of p53, p110Rb, p16, p21, p56Rb, p94Rb,
3 Rb56, and a functional variant of the Rb gene and the p53 gene.

1 **64.** (New) The method of claim 63, wherein said tumor suppressor
2 gene is a functional variant of the Rb gene and the p53 gene.

1 **65.** (New) The method of claim 61, wherein said administration of said
2 compound of Formula I is prior to the administration of said recombinant viral vector.

1 **66.** (New) The method of claim 61, wherein said administration of said
2 compound of Formula I is concomitant with the administration of said recombinant viral
3 vector.

1 **67.** (New) The method of claim 61, wherein the administration of said
2 compound of Formula I further comprises a solubilizing agent.
B/PAK

1 **68.** (New) The method of claim 61, wherein R is a cationic group
2 selected from the group consisting of NMe₃⁺ and NH₃⁺.

1 **69.** (New) The method of claim 61, wherein the saccharide group
2 comprises one or more pentose or hexose residues.

1 **70.** (New) The method of claim 61, wherein the saccharide group is
2 selected from the group consisting of pentose monosaccharide groups, hexose
3 monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose
4 disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose
5 disaccharide groups.


1 **71.** (New) The method of claim 61, wherein the saccharide group
2 comprises between three and about eight monosaccharide residues.

1 **72.** (New) The method of claim 61, wherein the saccharide group is a
2 trisaccharide.

1 **73.** (New) The method of claim 61, wherein at least one of X₂ and X₃
2 is a saccharide group.


1 **74.** (New) The method of claim 61, wherein m and n are each
2 independently 2 or 3.

1 **75.** (New) The method of claim 61, wherein X₁ and X₂ are both




3 and X₃ is a saccharide group.

1 **76.** (New) The method of claim 61, wherein said compound has
2 Formula III:




3


- 1 **77.** (New) The method of claim 61, wherein said compound has
2 Formula IV:




- 1 **78.** (New) The method of claim 61, wherein said compound has
2 Formula V:



- 1 **79.** (New) The method of claim 61, wherein said compound has
2 Formula II:




wherein X_1 and X_2 are selected from the group consisting of a



and X_3 is a saccharide group.

1 **80.** (New) The method of claim 61, wherein X_1 and X_2 are both

2



3 and X_3 is a glucose group.

1 **81.** (New) A method for treating bladder cancer by the administration
2 of a recombinant viral vector encoding a cytostatic or a tumor suppressor gene in
3 combination with a compound of Formula III:

*3¹
Cancelled*